Evofem Reports Fourth Consecutive Year of Net Sales Growth

-- 2024 Net Sales Increased 6% to $19.4 Million --

-- Total Operating Expense Reduced 27% from 2023 Levels, 
Excluding Non-cash Amortization Expense --

-- Sales and Marketing Expense as a Percentage of Net Sales was 47% for 2024 and
31% for the Fourth Quarter, the Most Favorable Ratios since the PHEXXI Launch --

Read more at prnewswire.com